Pure Capital Demands Replacement of Therapix Biosciences Ltd.'s Board of Directors
02 Junho 2020 - 9:00AM
Pure Capital today announces that it has sent a letter to the chief
executive officer, chairman of the board and the directors of
Therapix Biosciences Ltd. (NASDAQ: TRPX), calling for an immediate
general meeting of the shareholders of Therapix Biosciences and the
dismissal of all members of the board.
In the letter, Pure Capital detailed previous
actions which it believes have been harmful to shareholders. These
actions, taken by Therapix Biosciences, have not been in the best
interest of the company nor its shareholders, including, among
others, capital raises under unfavorable terms. Furthermore, Pure
Capital demanded that until the special general meeting is
convened, the company will not take any action not in the ordinary
course of business, including, without limitation, any dispositions
of its assets or securities offerings, whether public or private.
In addition, Pure Capital demanded that the board of directors of
the Company shall not appoint any additional directors to the
Company’s board of directors prior to the special general
meeting.
According to the Israeli Companies Law, the
meeting must be called no later than 21 business days from the date
of the demand letter.
About Pure Capital Ltd.
Pure Capital is a privately owned investment
company. Over the last two years, the firm has led various
transactions and capital raises totaling over $200 million in the
U.S, Canada and Israel.
Contact:
Michal Efraty+972-3-695-0380michal@efraty.com
Therapix Biosciences (NASDAQ:TRPX)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Therapix Biosciences (NASDAQ:TRPX)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024
Notícias em tempo-real sobre Therapix Biosciences Ltd da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de